Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population

Maryam Payan¹, Nader Tajik*², Mohammad Reza Rouini³
Mohammad Hossein Ghahremani⁴

Received: 7 February 2015 Accepted: 8 April 2015 Published: 3 October 2015

Abstract

Background: Cytochrome P450 2C19 (CYP2C19) is important in metabolism of a wide range of drugs. CYP2C19*17 is a novel variant allele which increases gene transcription and therefore results in ultra-rapid metabolizer phenotype (URM). Distribution of this variant allele has not been well studied worldwide. The aim of present study was to investigate allele and genotype frequencies of CYP2C19*17 in a healthy Iranian population and compare them with other ethnic groups.

Methods: One hundred eighty healthy unrelated Iranian volunteer took part in this study and were genotyped for CYP2C19 *2, *3, *17 (-3402) by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and CYP2C19*17 (-806) by a nested-PCR assays. The distribution of CYP2C19*17 polymorphism in Iranian population was then compared with other ethnic groups.

Results: The CYP2C19*17 allele frequency was 21.6% in Iranian population. Among studied subjects 5.5% were homozygous for CYP2C19*17 and phenotyped as ultra-rapid metabolizers; 28.8% were genotyped as CYP2C19*1*17 (extensive metabolizers) and 3.3% as CYP2C19*2*17 (intermediate metabolizers).

Conclusion: The CYP2C19*17 genetic distribution in Iranian population is similar to Middle East or European countries. The high frequency of CYP2C19*17 in Iranian population highlights the importance of this new variant allele in metabolism of CYP2C19 substrates. Thus, future association studies are required to reveal clinical consequence of this genetic polymorphism in carrier individuals.

Keywords: CYP2C19, Genotyping, Iranian, Polymorphism, Polymerase chain reaction.

Cite this article as: Payan M, Tajik N, Rouini MR, Ghahremani MH. Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population. Med J Islam Repub Iran 2015 (3 October). Vol. 29:269.

Introduction

The cytochrome P450 2C19 (CYP2C19) is important in metabolism of a wide range of drugs including proton pump inhibitors (omeprazole), tricyclic antidepressants (amitriptyline), selective serotonin reuptake inhibitors (citalopram), anticonvulsant S-mephentoin and anti-platelet drugs (clopidogrel) (1-3).

Genetic polymorphism of CYP2C19 was identified by its considerable effect in metabolism of S-mephyntoin, resulting in poor metabolizer (PM) and extensive metabolizer (EM) (4). The EM phenotype is attributed to wide type allele (CYP2C19*I). The PM is assigned to CYP2C19*2 which is defined as a mutation in exon 5 (CYP2C19, 681G>A) and causes a splice

¹. PhD candidate, Biopharmaceutics and Pharmacokinetics Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical sciences, Tehran, Iran. payan@razi.tums.ac.ir
². (Corresponding author) Professor of Immunology, Immunology Research Center (IRC), Iran University of Medical Sciences, Tehran, Iran. nadertajik@yahoo.com, tajik.n@iums.ac.ir
³. Professor, Biopharmaceutics and Pharmacokinetics Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical sciences, Tehran, Iran. rouini@tums.ac.ir
⁴. Professor, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical sciences, Tehran, Iran. mhghahremani@razi.tums.ac.ir
CYP2C19*17 polymorphism in Iranian population

http://mjiri.iums.ac.ir

Two studies have reported allelic frequency of CYP2C19*17 and its effect on clinical response to CYP2C19 substrates (8,10-13). CYP2C19*17*17 genotype has been found to increase clinical response to clopidogrel treatment by better anti-platelet activity and therefore was associated with higher risk of bleeding (14). In treatment of peptic ulcer, URM phenotype, caused the therapeutic failure by increasing proton pump inhibitor metabolism (15) and PM phenotype led to greater acid suppression (16,17). Several studies show inter-ethnic differences in distribution of this variant allele (1,6,17). The allele frequency of CYP2C19*17 was estimated 18% in Swedish, 4% in Chinese (6) and 1.7% in Japanese people (1). To our best knowledge, no study has been conducted to evaluate distribution of this new variant allele in Iranian population. Thus, the present study aims to investigate allele and genotype frequencies of CYP2C19*17 variant in the Iranian population and compare these frequencies with other ethnic groups. These findings would help us to estimate importance of this new polymorphism in variable response to CYP2C19 substrates between Iranian individuals.

Methods
Subjects and DNA extraction
One hundred and eighty unrelated healthy Iranian volunteers (60 women and 120 men) with the mean age of 36 years (ranging between 20 and 55) and average body weight of 63 kg (ranging between 45 and 89) took part in this study. A randomize prospective cross sectional design was used to recruit participants. All subjects were students or stuffs of faculty of pharmacy from four different cities in Iran. They signed written informed consent before attending this project. The study protocol was confirmed by ethics committee of Tehran University of Medical Sciences.

Five ml venous blood sample was taken from each subject and transferred into tubes containing 10 µl of 10% ethylene diamine tetra-acetic acid (EDTA). Genomic DNA was obtained from peripheral blood leucocytes by salting out method (using supersaturated 6M NaCl solution) (18). The extracted DNA was dissolved in sterile distilled water and stored at 4°C until the day of analysis.

Genotyping of CYP2C19*2 (681G>A), CYP2C19*3 (636G>A) and CYP2C19*17 (-3402C>T)
The genotyping of CYP2C19*2 (681G>A), CYP2C19*3 (636G>A), and CYP2C19*17 (-3402C>T) polymorphisms was performed by modified PCR-RFLP assays as originally described by De Morais et al. (19) and Sim et al. (6). The PCR reaction mixture (25 µl) was consisted of 250 ng template DNA, 1× PCR buffer, 2 mM MgCl2, 0.2-0.8 µM of each specific forward and reverse primers, 0.2 mM dNTPs, 1 Unit of Taq DNA polymerase (CinnaGen, Iran) and sterile distilled water. The PCR reaction was carried out in an Eppendorf PCR system gradient master cycler (Hamburg, Germany). Thermal profile for DNA amplification was as follows: the initial denaturation at 94°C for 2 min; then 35 cycles of denaturation at 94°C for 45 seconds, annealing at 53°C for 40 seconds, and extension at 72°C for 30 seconds; final extension at 72°C for 5 min eventually applied to cycling. All three PCR reactions were amplified by similar thermal profile. The PCR product of each reaction was digested by specific restriction endonuclease (New England Biolabb, UK). The details of primers sequence and restriction enzymes are summarized in Table 1. Smal digested the 169 bp fragment to 120 and 49 bp fragments in wild type (wt) carriers of CYP2C19*17 polymorphism in Iranian population

2 Med J Islam Repub Iran 2015 (3 October). Vol. 29:269.
CYP2C19*1. BamHI yielded 233 and 96 bp fragments in wild type carriers of CYP2C19*1. MnlI resulted in 280 and 224 bp fragments in wt subjects for CYP2C19*1. While the homozygous carriers of CYP2C19*2, *3 and *17 were resistant to digestion by related enzymes and resulted in single band in the 2.5% agarose gel stained with ethidium bromide (Table 1).

Genotyping of CYP2C19*17 (-806C>T)
The CYP2C19*17 -806C>T mutation was analyzed by semi-nested PCR approach as described by Sim et al. with a few modifications (6). The first PCR reaction mixture and thermal protocol (PCR I) was identical to what described earlier for CYP2C19*2, *3 and *17(-3402); R1 and F1 primers (Table 1) yielded a 470 bp product. 0.5 μl of PCR I product was then included in second allele-specific PCR reactions (PCR II). Primer F2 (wt) or primer F3 (mt) were used with primer R1 to differentiate between -806C (CYP2C19*1) and -806T (CYP2C19*17) alleles, respectively. The reaction mixture (15 μl) of PCR II (one reaction for each allele) was similar to that of first reaction, except for using 2.5 mM MgCl2. The second reaction (PCR II) was performed with initial denaturation at 94°C for 1 min, and then 15 cycles at 94°C for 15 seconds, annealing at 53°C for 20 seconds and extension at 72°C for 30 seconds. The 200 bp PCR products (wt or mt) were separated by 2.5% agarose gel.

Statistical analysis
The allele frequency differences between populations were estimated using Chi-square test and two tailed Fisher’s exact test. The 95% confidence intervals (CIs) were calculated using Confidence Interval Analysis software. The relation of sex and genotype was analyzed by two tailed Fisher’s exact test. The observed and expected frequencies were calculated using Hardy-Weinberg equation. The two tailed Fisher’s exact test was used to assess genotype frequencies deviation in the studied population from Hardy-Weinberg equilibrium. In all statistical analysis p<0.05 was considered as significant difference.

Results
The CYP2C19*17 allele was identified in 78 out of 180 volunteer with the frequency of 21.6% (95% CI: 17.5 – 26.3). 10 subjects were homozygous for CYP2C19*17 (5.5%, 95% CI: 2.7-10 %), 52 subjects (28.8%, 95% CI: 22.4-36.1 %) were heterozygous for CYP2C19*17 and 75 subjects (41.7%, 95% CI: 34.4-49.2%) were found to be homozygous for CYP2C19*1. The genotype and allele frequencies of CYP2C19 are reported in Table 2. The dis-
distribution of CYP2C19*17 and CYP2C19*2 polymorphisms were not statistically different in the studied men and women (p>0.05). The expected frequencies of CYP2C19 genotypes in Iranian population in this study, had no significant deviation from the Hardy-Weinberg equilibrium (p>0.05). Complete linkage disequilibrium was observed in -806 C>T with that of -3402C>T and this observation was in accordance with previously published studies (1,6,13,20). Both -806 C>T and -3402C>T mutations were not observed in subjects homozygous for CYP2C19*2 and accordingly CYP2C19*2 allele was not detected in subjects homozygous for CYP2C19*17. CYP2C19*2 allele was present in 43 individuals (with the frequency of 13.1%; 95% CI: 9.7-16.9 %). Four subjects were homozygous for CYP2C19*2 (2.2%, 95% CI: 0.6-5.5%) and 39 subjects were heterozygous for CYP2C19*2 (21.6%, 95% CI: 15.8-28.4%). Six out of these 39 subjects had both CYP2C19*17 and CYP2C19*2 alleles (3.3%, 95% CI: 1.2-7.1%) and were genotyped as CYP2C19*2*17, and the rest of 33 subjects were combination of CYP2C19*1 and CYP2C19*2 alleles (18.3%; 95% CI: 13.0-24.7%) and were genotyped as CYP2C19*1*2. CYP2C19*3 was not identified in our study population. Based on the CYP2C19 genotypes, subjects were divided into 4 previously defined phenotypes (2); the summary of predicted phenotypes is shown in Table 2. Homozygous carriers of CYP2C19*17 allele were categorized as ultra-rapid metabolizers (URM). Subjects with CYP2C19*1*17 and CYP2C19*1*1 genotypes were designated as extensive metabolizer (EM). Individuals with CYP2C19*2*17 and CYP2C19*1*2 genotypes were classified as intermediate metabolizers (IM) and homozygous carrier of CYP2C19*2 were stratified as poor metabolizers (PM).

The allele and genotype frequencies of CYP2C19 in this study were also compared with previously published reports. Data are summarized in Table 3 and Table 4. According to the data in the Table 3, the allele frequency of CYP2C19*17 in this study was not statistically different from European and Middle East countries. For example, the frequency of CYP2C19*17 allele was 20% in Swedish, 20.1 % in Danish, 22% in Norwegian, 19.6% in Greek, 24.4% in Turkish and 25.7% in Saudi Arabian people (6,9,21,23) while in the East and South Asia like Korea, Thailand and Japan, there was an statistically significant difference in allele frequency of CYP2C19*17 with European and Middle East countries (p< 0.05) (1,2,4,25).

**Discussion**

CYP2C19 is an important factor in the pharmacokinetic of CYP2C19 substrates like clopidogrel, imipramine, escitalopram and proton pump inhibitors (PPIs) (12,13,15,20, 28). CYP2C19*17 variant

### Table 2. CYP2C19 genotype and allele frequencies and expected phenotype in 180 healthy Iranian individuals

| CYP2C19 Genotype | Number of subjects | Frequency (%) | 95% CI | Predicted Phenotype | Expected frequency by Hardy-Weinberg low *% |
|------------------|--------------------|---------------|--------|---------------------|------------------------------------------|
|                  | Men (120) | Women (60) |        |                    |                                          |
| *1*1*17         | 5        | 5          | 5.5    | 2.7-10.0       | URM                                      |
| *1*1*2*17       | 37       | 15         | 28.8   | 22.4-36.1      | EM                                       |
| *2*1*17         | 53       | 22         | 41.7   | 34.4-49.2      | EM                                       |
| *2*1*2*17       | 20       | 13         | 18.3   | 13.0-24.7      | IM                                       |
| *1*1*2*17       | 4        | 2          | 3.3    | 1.23-7.1       | IM                                       |
| *2*1*2*17       | 2        | 2          | 2.2    | 0.6-5.5        | PM                                       |
| *2*1*3*17       | 0        | 0          | 0      | 0.1-0.9        | 0                                        |

| Alleles | No. of alleles | Frequency (%) | 95% Confidence Interval |
|---------|----------------|---------------|-------------------------|
| CYP2C19*17 | 78           | 21.6         | 17.5-26.3               |
| CYP2C19*1   | 235          | 65.3     | 60.1-70.2               |
| CYP2C19*2   | 47           | 13.1     | 9.7-16.9                |
| CYP2C19*3   | 0            | 0           | 0                       |

**Abbreviations:** UM, Ultra-rapid metabolizer; Het-EM, Heterozygous extensive metabolizer, EM, Extensive metabolizer; IM, Intermediate metabolizer; PM, Poor metabolizer. CI: Confidence Interval

*Observed and expected frequencies were not statistically different (p>0.05).*
Table 3. Comparison of CYP2C19 allele frequencies between Iranians and different populations

| Population       | Sample size | CYP2C19 Allele Frequency (%) | Reference |
|------------------|-------------|------------------------------|-----------|
| Iranian          | 180         | 21.7 (19*17), 65.3 (19*1), 13.0 (19*2), 0 (19*3), 0 (Others) | Present study |
| Japanese         | 165         | 1.3 (19*17), 57.9 (19*1), 27.9 (19*2), 12.8 (19*3), 0 (Others) | 1         |
| Swedish          | 314         | 18.0 (NR), 18.0 (NR), 0 (NR), 0 (NR), 0 (Others) | 6         |
| Ethiopian        | 190         | 18.0 (NR), 18.0 (NR), 0 (NR), 0 (NR), 0 (Others) | 6         |
| Chinese          | 68          | 4.0 (NR), 64.9 (NR), 15.0 (NR), 0 (NR), 0 (Others) | 6         |
| Danish           | 276         | 20.1 (NR), 64.9 (NR), 15.0 (NR), 0 (NR), 0 (Others) | 9         |
| Faroese          | 311         | 15.4 (NR), 65.9 (19*1), 18.7 (19*2), 0 (19*3), 0 (Others) | 9         |
| Norwegian        | 309         | 22.0 (NR), 62.8 (NR), 15.2 (NR), 0 (NR), 0 (Others) | 9         |
| Polish           | 78          | 28.2 (NR), 56.4 (NR), 15.4 (NR), 0 (NR), 0 (Others) | 10        |
| Greek            | 283         | 19.6 (NR), 67.3 (NR), 13.0 (NR), 0 (NR), 0 (Others) | 21        |
| Saudi Arabian    | 201         | 25.7 (NR), 62.9 (NR), 11.2 (NR), 0 (NR), 0 (Others) | 22        |
| Turkish          | 244         | 24.4 (NR), 65.6 (NR), 10.0 (NR), 0 (NR), 0 (Others) | 23        |
| Korean           | 150         | 0.3 (NR), 61.0 (NR), 28.0 (NR), 11.0 (NR), 0 (NR), 0 (Others) | 24        |
| Swedish          | 185         | 20.0 (NR), 64.0 (NR), 16.0 (NR), 0 (NR), 0 (Others) | 24        |
| Thai             | 1051        | 4.0 (NR), 63.0 (NR), 27.0 (NR), 6 (NR), 0 (Others) | 25        |
| Indian           | 206         | 17.9 (NR), 42.0 (NR), 40.2 (NR), 0 (NR), 0 (Others) | 26        |
| Korean           | 271         | 1.5 (NR), 60.0 (NR), 28.4 (NR), 10.1 (NR), 0 (Others) | 27        |
| German           | 186         | 25.5 (NR), 59.3 (NR), 15.2 (NR), 0 (NR), 0 (Others) | 28        |
| Ashkenazi Jewish | 342         | 13.0 (NR), 70.0 (NR), 12.0 (NR), 0 (NR), 0 (Others) | 29        |
| African American | 149         | 19.0 (NR), 63.0 (NR), 12.0 (NR), 0 (NR), 0 (Others) | 29        |
| Hispanic         | 346         | 10.0 (NR), 75.0 (NR), 10.0 (NR), 0 (NR), 1.74 (NR) | 29        |

NR: Not reported.

* Represent statistically significant difference in comparison to present data (p<0.05).

Table 4. Comparison of CYP2C19 genotype frequencies between Iranians and different populations

| Population       | Sample Size | CYP2C19 genotype frequency (%) | Reference |
|------------------|-------------|--------------------------------|-----------|
| Iranian          | 180         | 5.5/17, 28.9/17, 41.7/17, 3.3/17, 183/2, 183/3/1, 2/3/3/3 | Present Study |
| Japanese         | 165         | 0.0/17, 1.1/17, 35.5/17, 1.5/17, 43.8/17, 18.8/1, 18.8/3 | 1         |
| Danish           | 276         | 5.1/17, 22.8/17, 44.2/17, 7.3/17, 18.5/17, 2.2/1, 2.2/3 | 9         |
| Faroese          | 311         | 3.5/17, 16.4/17, 46/17, 7.4/17, 23.5/17, 3.2/1, 3.2/3 | 9         |
| Norwegian        | 309         | 4.9/17, 26.5/17, 39.5/17, 7.8/17, 20.1/17, 1.3/1, 1.3/3 | 9         |
| Greek            | 283         | 3.2/17, 28.6/17, 44.1/17, 4.3/17, 17.8/17, 2.1/1, 2.1/3 | 21        |
| Saudi Arabian    | 201         | 7.0/17, 30.4/17, 40.3/17, 7.0/17, 14.5/17, 0.4/0.4, 22 | 22        |
| Turkish          | 244         | 6.6/17, 30.3/17, 44.3/17, 5.3/17, 12.3/17, 1.2/1, 1.2/3 | 23        |
| Thai             | 1051        | 0.0/17, 4.3/17, 40.7/17, 0.0/17, 35.1/17, 6.85/17, 7.3/5.6/17, 0.1/25 | 25        |
| Indian           | 206         | 1.2/17, 20.7/17, 16.1/17, 12.6/17, 31.0/17, 18.4/17, 26 | 26        |
| Korean           | 271         | 0.0/17, 1.1/17, 35.7/17, 1.4/0.3, 36.3/17, 6/10.7, 5.9/7.0/11 | 27        |

* Represent statistically significant difference in comparison to present data (p<0.05).

that was identified by Sim et al. and reported to be associated with higher metabolic activity of CYP2C19. This variant allele has a different genetic distribution in various ethnic groups (6). Several studies have shown the effect of CYP2C19*17 polymorphism on treatment of peptic ulcer disease (10,15,20,30). The data in the different studies indicate that CYP2C19*17 is associated with 2.1 fold lower omeprazole plasma concentration and therefore the efficacy of PPIs like omeprazole is decreased in CYP2C19*17*17 individuals (10,15,20). Musumba et al. investigated the effect of CYP2C19*17 allele on occurrence of peptic ulcer disease (PUD) and showed increased prevalence of PUD in patient with CYP2C19*17*17 genotype in comparison to CYP2C19*1*1 genotype (30). CYP2C19*17 allele also leads to lower risk of breast cancer by increasing estrogen metabolism (31).

The distribution of CYP2C19*17 polymorphism has not been well estimated worldwide. The main goal of present study was to investigate allele and genotype frequencies of CYP2C19*17 in Iranian population. In this study the allele frequency of CYP2C19*17, *2 and *1 were 21.6%, 13.1% and 65.3% respectively which is in agreement with previous study in our lab for CYP2C19*2 and *1 (32). In our previ-
ous study subjects that were genotyped as CYP2C19*1*17 and CYP2C19*1*17 in this study were identified as CYP2C19*1*17. So, if genotype frequencies of CYP2C19*1*17 and CYP2C19*1*17 (28.8% and 5.5%) is deduced from CYP2C19*1*1 genotype frequency in previous report (75%), the similar frequency for CYP2C19*1*1 (40.55%) is attained. Accordingly, people with CYP2C19*2*17 in this study were defined as CYP2C19*1*2 in previous report, so, if we recalculate the CYP2C19*1*2 genotype frequency by deduction of the CYP2C19*2*17 frequency in this study (3.3%) form CYP2C19*1*2 genotype frequency in the previous study (22%), the frequency of 18.7% for CYP2C19*1*2 is obtained which is similar to the result of this study (18.3%).

Based on the results of this study, there is not a significant difference in distribution of CYP2C19*17 variant allele in Iranian population compared with European and other Middle East countries. In contrast, east and south Asian people have significantly lower frequency of this polymorphism than Iranians.

CYP2C19*2 allele reduces enzyme activity and CYP2C19*17 allele increases enzyme activity (6). In this study, subjects with CYP2C19*2*17 were categorized as IM. Few studies have reported effect of CYP2C19*2*17 on metabolic capacity of this enzyme (2,13,21,26). In the study by Gurbel et al. (2) the CYP2C19 activity in stented patients treated with clopidogrel was similar in both CYP2C19*2*17 and CYP2C19*1*2 genotypes. Therefore, it was concluded that in patients carrying both *2 and *17 alleles the reduction of enzyme activity by *2 allele is more predominant than induction of enzyme activity by *17 allele, consequently, in this study CYP2C19*2*17 genotype was classified as IM.

Finally, although genotype-based phenotype prediction is not the best and complete way for estimation of protein activity because other factors like sex, age and associated disease, combination therapy and environmental factors may influence this relationship, the high frequency of CYP2C19*17 in Iranian population makes this new variant allele suitable candidate for association studies and help us to reveal clinical consequences of this genetic polymorphism in carrier individuals.

**Conclusion**

The allele frequency of CYP2C19*17 in Iranian population is 21.6% and is similar to Middle East or European countries. The high frequency of CYP2C19*17 allele in Iranian population highlights the importance of this new variant allele in metabolism of CYP2C19 substrates. Future association studies are required to reveal clinical consequence of this genetic polymorphism in carrier individuals.

**Acknowledgements**

This project was supported by a grant from Drug Design and Development Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

**References**

1. Sugimoto K, Uno T, Yamazaki H, Tateishi T. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 2008;65(3): 437–9.
2. Gurbel PA, Shuldiner AR, Bliden KP, Ryan K, Pakyz RE, Tantry US. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J 2011; 161(3): 598-604.
3. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishazaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004; 5(2): 181-202.
4. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Therapeut 2013; 138(1): 103-41.
5. Rosemary J, Adithan C, Padmaja N, Shashindran CH, Gerard N, Krishnamoorthy R. The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in south Indians. Eur J Clin Pharmacol 2005; 61(1): 19-23.
6. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism in South Indians. Pharmacogenet Genomics 2007; 17(1): 11-20.
metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79(1): 103–13.

7. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphism on drug therapies: Pharmacogenetic and clinical aspects. Pharmacol Therapeut 2007; 116: 496–526.

8. Wang G, Lei HP, Li Z, Tan ZR, Guo D, Fan L, et al. The CYP2C19 ultra rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 2009; 65(3): 281–5.

9. Pedersen RS, Brasch-Andersen C, Sim SC, Bergmann TK, Halling J, Petersen MS, et al. Linkage disequilibrium between the CYP2C9*17 allele and wide type CYP2C8 and CYP2C9 alleles: identification of CYP2C9 haplotypes in healthy Nordic population. Eur J Clin Pharmacol 2010; 66: 1199-205.

10. Kurzawski M, Gawrońska-Szklarz B, Wrześniewska J, Siuda A, Starzyńska T, Drożdžik M. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patient. Eur J Clin Pharmacol 2006; 62: 877-80.

11. Chen L, Qin S, Xie J, Tang J, Yang L, Shen W, et al. Genetic polymorphism analysis of CYP2C19 in Chinese Han population from different geographic areas of mainland China. Pharmacogenomics 2008; 9(6): 691-702.

12. Schenck PW, van Vliet M, Mathot RA, van Gelder T, Vulto AG, van Fessem MA, et al. The CYP2C19*17 genotype is associated with lower imipramine plasma concentration in a large group of depressed patient. Pharmacogenomics J 2010; 10(3): 219-25.

13. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients. Clin Pharmacol Ther 2008; 83(2): 322-7.

14. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in Clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121(4): 512-8.

15. Hunfeld NG, Mathot RA, Touw DJ, van Schaik RH, Mulder PG, Franck PF, et al. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol 2008; 65(5): 752-60.

16. Hagymási K, Müllner K, Herszényi L, Tulas-say Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2011; 12(6): 873–88.

17. Kawabata H, Habu Y, Tomioka H, Kutsumis H, Kobayashi M, Oyasu K, et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 2003; 17(2): 259–64.

18. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.

19. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. Mol Pharmacol 1994; 46: 594-8.

20. Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E, Bertilsson L. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 2008; 65(5): 767-74.

21. Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG. Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics 2009; 10(1): 43-9.

22. Saeed LH, Mayet AY. Genotype-Phenotype analysis of CYP2C19 in healthy Saudi individuals and its potential clinical implication in drug therapy. Int J Med Sci 2013; 10(11): 1497-502.

23. Gumus E, Karaca O, Babaoglu MO, Baysel G, Balamtekin N, Demir H, et al. Evaluation of Lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood. Eur J Clin Pharmacol 2012; 68(5): 629-36.

24. Ramsjö M, Aklillu E, Bohman L, Ingelman-Sundberg M, Roh HK, Bertilsson L. CYP2C19 activity comparison between Swedish and Koreans: effect of genotype, sex, oral contraceptive use and smoking. Eur J Clin Pharmacol 2010; 66(9): 871-7.

25. Sakasegawa T, Munakata Y, Hattori S, Yamakawa T, Sanjo K, et al. Genetic polymorphism of CYP2C19 in Japanese: correlation with atherothrombotic risk factors. Pharmacogenomics J 2010; 10(1): 28-36.

26. Anichavezhi D, Chakradhara Roa US, Shewade DG, Krishnamoorthy R, Adithan C. Distribution of CYP2C19*17 allele and genotype in an Indian population. J Clin Pharm Ther 2012; 37(3): 313-8.

27. Kim KA, Song WK, Kim KR, Park JY. Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles. J Clin Pharmacol Ther 2010; 35(6): 697–703.

28. Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, et al. CYP2C19 and nongenetic factors predict poor responsiveness to...
CYP2C19*17 polymorphism in Iranian population

8 Med J Islam Repub Iran 2015 (3 October). Vol. 29: 269.

http://mjiri.iums.ac.ir

29. Strom CM, Goos D, Crossley B, Zhang K, Buller-Burkle A, Jarvis M, et al. Testing for variant in CYP2C19: population frequencies and testing experience in clinical laboratory. Genet Med 2012; 14 (1): 95-100.

30. Musumba CO, Jorgensen A, Sutton L, Eker DV, Zhang E, Hara NO, et al. CYP2C19*17 Gain-of-function polymorphism is associated with peptic ulcer disease. Clin Pharmacol Ther 2013; 93(2): 195-203.

31. Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S, et al. CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat 2009; 115(2): 391-6.

32. Zand N, Tajik N, Moghaddam AS, Milanian I. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol 2007; 34(1-2): 102-5.